Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
News|Articles|June 2, 2024
Psychedelics Recommendations Poll
Author(s)Psychiatric Times Editors
Answer a quick question on psychedelics!
Advertisement
If approved by the FDA, would you recommend psychedelics to your patients as an option?
Advertisement
Related to this article
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
2
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
3
Promoting Literacy to Improve Child Development: Reading Model Boosts Efforts
4
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
5